WO2011001676A1 - 表面麻酔剤 - Google Patents
表面麻酔剤 Download PDFInfo
- Publication number
- WO2011001676A1 WO2011001676A1 PCT/JP2010/004312 JP2010004312W WO2011001676A1 WO 2011001676 A1 WO2011001676 A1 WO 2011001676A1 JP 2010004312 W JP2010004312 W JP 2010004312W WO 2011001676 A1 WO2011001676 A1 WO 2011001676A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- lidocaine
- ethyl paraaminobenzoate
- anesthetic
- adrenaline
- mass
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
- A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to a surface anesthetic agent which exhibits an anesthetic effect within 3 minutes after application or spraying, comprising lidocaine and ethyl paraaminobenzoate, preferably lidocaine, ethyl paraaminobenzoate and adrenaline as active ingredients.
- surface anesthesia is anesthesia performed to alleviate the pain of the injection needle when performing infiltration anesthesia or transmission anesthesia by applying or spraying an anesthetic agent on the mucous membrane or skin, and then performing infiltration anesthesia or transmission anesthesia by injection. Yes, it is mainly applied to dental treatments such as children.
- Infiltration anesthesia is a method in which an infiltrated portion is anesthetized by injection, and is partially anesthetized.
- a tooth is extracted or sharpened, or for surgery, a simple incision operation is performed.
- Transmission anesthesia is a method in which an anesthetic is injected near the nerve and anesthesia is performed up to the tip where the nerve is running. In dentistry, it is injected mainly around the nerve that enters the bone of the mandible. This is a method of anesthesia from the back teeth to the front teeth.
- ester type Local anesthetics are generally classified into ester type, amide type or anilide type.
- ester type include benzoic acid esters such as cocaine, tropacocaine, procaine, tetracaine, piperocaine, and stovereine, alkoxybenzoic acid esters such as cyclomethicaine and paretoxycaine, and aminobenzoic acid such as methyl paraaminobenzoate and ethyl paraaminobenzoate.
- acid esters and as amide or anilide type, lidocaine (xylocaine) and the like are known.
- vasoconstrictors such as epinephrine (adrenaline) and catecholamines such as norepinephrine are used for the purpose of sustaining the effect, and as a storage stabilizer, butylhydroxytoluene, gallic acid esters, etc.
- Antioxidants, stabilizers such as gelatin, agar, starch, thiourea, citric acid, L-methionine, glutamic acid, fructose, sucrose, lactose and thioglycerin, or sweeteners and thickeners especially for oral surface anesthetics Is included to constitute a local anesthetic.
- Patent Document 1 As an improvement of the surface anesthetic agent, a conventional method for increasing its durability (for example, Patent Document 1, Patent Document 2, Patent Document 5 and the like), a method for quickly releasing anesthesia after surgery (for example, Patent Document 3), an anesthetic agent, etc.
- Patent Document 4 the proposed methods for improving the storage stability
- Patent Document 5 the immediate effect of the surface anesthetic is improved by mixing lidocaine, prilocaine and tetracaine.
- Patent Document 6 a percutaneous anesthetic
- Patent Document 6 only about 55.7% of humans became pain “0” 30 minutes after application.
- Patent Document 7 a skin external preparation having an effect of improving pruritus mixed with a local anesthetic, urea, a cooling agent, alcohol and water, or a local anesthetic is applied to the outer surface of the wound part.
- a method for suppressing or improving pain from a surgically closed wound for example, Patent Document 8) has been proposed, but there is no disclosure that immediate effect is improved for a local anesthetic used.
- Japanese Patent No. 4060884 JP 2002-275093 A Special table 2003-532678 gazette Japanese Patent Laid-Open No. 9-77662 Japanese Patent Laid-Open No. 10-306040 JP 2006-527734 Gazette JP 2007-262030 A Special table 2003-512401 gazette
- Surface anesthesia is a preliminary treatment that avoids pain caused by the injection needle for full-scale anesthesia mainly by the next injection, etc., and generally does not need to last for a long time, but it is effective immediately after the measure. It is important that it be obtained. For example, when performing a dental operation such as extraction, a surface anesthetic is first applied, and infiltration anesthesia is performed after anesthesia is effective. In the case of commercially available surface anesthetics, it takes 3 to 5 minutes for the surface anesthesia to be effective. Meanwhile, the surgeon must wait without doing anything. This waiting time is not comfortable for the patient and is a loss of time.
- An object of the present invention is to provide a rapid-acting surface anesthetic agent that can obtain an effect faster after application or spraying.
- lidocaine [2- (diethylamino) -N- (2,6-dimethylphenyl) acetamide]
- adrenaline as a vasoconstrictor.
- the combination was examined.
- lidocaine and adrenaline are used in combination, the immediate effect of the surface anesthetic action gradually increases as the amount of adrenaline added increases, but the use of a large amount of adrenaline may cause side effects and is not preferable.
- ethyl paraaminobenzoate was used in combination with adrenaline instead of lidocaine, no immediate effect of surface anesthetic action was observed even when the amount of adrenaline added was increased.
- the present invention relates to (1) a surface anesthetic agent containing lidocaine and ethyl paraaminobenzoate in a mass ratio of 1:99 to 47:53, and (2) a mass ratio of lidocaine and ethyl paraaminobenzoate of 6:
- the surface anesthetic described in (1) above in a ratio of 94-18: 82 (3) the surface anesthetic described in (1) or (2) above containing adrenaline in addition to lidocaine and ethyl paraaminobenzoate, (4)
- the surface anesthetic agent according to any one of (1) to (3) above, containing 0.1 to 0.001 parts by mass of adrenaline with respect to 100 parts by mass of lidocaine and ethyl paraaminobenzoate.
- the present invention also relates to (5) a method of using a composition containing lidocaine and ethyl paraaminobenzoate in a mass ratio of 1:99 to 47:53 for the production of a surface anesthetic, and (6)
- the method according to (5) above comprising lidocaine and ethyl paraaminobenzoate in a mass ratio of 6:94 to 18:82, and (7) the composition further contains adrenaline in lidocaine and ethyl paraaminobenzoate.
- (9) a method of using a composition containing lidocaine and ethyl paraaminobenzoate in a mass ratio of 1:99 to 47:53 as a surface anesthetic, and (10) a composition comprising lidocaine And ethyl paraaminobenzoate in a mass ratio of 6:94 to 18:82, and the method according to (9) above, or (11) the composition further comprises adrenaline in addition to lidocaine and ethyl paraaminobenzoate ( 9) or the method according to (10), and (12) the composition contains 0.1 to 0.001 part by mass of adrenaline with respect to 100 parts by mass of lidocaine and ethyl paraaminobenzoate (9 ) To (11).
- an anesthetic effect is prominently exhibited within 3 minutes, especially 1 to 2 minutes after application or spraying to the mucous membranes and gums in the oral cavity, and no immediate pain is felt even after injection.
- An anesthetic can be provided.
- the surface anesthetic of the present invention is also effective for the skin, but in that case, it may take 5 to 6 minutes later to be effective than for the mucous membrane.
- lidocaine and ethyl paraaminobenzoate of the present invention Comparison of the combined use of lidocaine and ethyl paraaminobenzoate of the present invention, combined use of lidocaine, ethyl paraaminobenzoate and adrenaline, ethyl paraaminobenzoate used in the past, and the onset time and duration of lidocaine alone. It is a graph to show. In FIG. 1, the vertical axis represents the degree of pain when the needle is stabbed, and “5” represents a case where no anesthesia was performed, and “0” represents that no pain is felt at all. It is. The horizontal axis is time (minutes).
- this invention is a graph showing the relationship between the mixing
- the vertical axis represents the time (minutes) after application before anesthesia until pain is not felt by the injection needle
- the horizontal axis represents the blending ratio (mass ratio) of lidocaine and ethyl paraaminobenzoate.
- It is a graph which shows the effect of the adrenaline in the anesthetic of this invention and the existing anesthetic about time until it stops feeling the pain by an injection needle after application
- FIG. 4 It is a graph showing the relationship between the mixing ratio (mass ratio) of lidocaine (xylocaine) and tetracaine (corporon) used conventionally, and the time to the onset of an anesthetic effect.
- the vertical axis represents the degree of pain when the needle is stabbed, “5” indicates that the patient is not anesthetized at all, and “0” indicates that no pain is felt at all. It is.
- the horizontal axis is time (minutes).
- Examples of the surface anesthetic of the present invention include an anesthetic containing lidocaine and ethyl paraaminobenzoate in a mass ratio of 1:99 to 47:53, such as lidocaine having a concentration of 2% by mass and paraaminobenzoic acid having a concentration of 20% by mass.
- lidocaine having a concentration of 2% by mass
- paraaminobenzoic acid having a concentration of 20% by mass.
- ethyl it is not particularly limited as long as it is an anesthetic containing a ratio of 8:92 to 90:10, and the method of using the present invention includes lidocaine and ethyl paraaminobenzoate.
- lidocaine and ethyl paraaminobenzoate are local anesthetics as long as they are used for the production of a surface anesthetic. And it is known, these lidocaine and para ethyl benzoate may advantageously be used commercially.
- the mass ratio of lidocaine to ethyl paraaminobenzoate in the surface anesthetic agent of the present invention or the method of use of the present invention is a ratio of 3:97 to 31:69, for example, a concentration of 2% by mass of lidocaine and a concentration of 20% by mass.
- a ratio such that the blending ratio when using ethyl paraaminobenzoate is 25:75 to 82:18 is preferable from the viewpoint of immediate effect of the surface anesthetic action, and particularly a ratio of 6:94 to 18:82, for example, a concentration of 2 A ratio of 40:60 to 70:30 in the case of using mass% lidocaine and 20 mass% ethyl paraaminobenzoate is more preferable in terms of immediate effect of the surface anesthetic action.
- Lidocaine is a white to slightly yellow crystal or crystalline powder, and is known as an antiarrhythmic agent in addition to local anesthetics. It is also effective for symptoms of neuralgia and numbness in the limbs. It is sold as “Xylocaine”, which is also called “Lidoca” or “Xylo” among medical personnel.
- Xylocaine which is also called “Lidoca” or “Xylo” among medical personnel.
- lidocaine salts such as hydrochloride of lidocaine.
- ethyl paraaminobenzoate is a white crystal or crystalline powder, used as a local anesthetic as a pharmaceutical, and has a strong action of absorbing ultraviolet rays as a cosmetic, so sunscreen cream, foundation, lipstick, cream, Used in latex.
- adrenaline (R) -4- (1-hydroxy-2- (methylamino) ethyl) benzene-1,2-diol
- a small amount for example, lidocaine.
- 0.001 to 0.1 parts by weight preferably 0.001 to 0.1 parts by weight, and more preferably 0.003 to 0.03 parts by weight, with respect to 100 parts by weight of the total amount of ethyl and paraaminobenzoate Can do.
- Adrenaline is known as a substance having a vasoconstrictive action, and is generally used to maintain the durability of the effect of local anesthesia.
- a surface anesthetic a substance that significantly accelerates the effect. It is used as However, naturally the sustainability of the effect also increases.
- Adrenaline has effects such as raising heart rate and blood pressure, opening pupils, raising blood sugar level, etc., so it may adversely affect elderly people, children or those with heart disease or diabetes. It is desirable to use as small amounts as possible.
- the surface anesthetic of the present invention is an anesthetic that exhibits an anesthetic effect immediately after application, preferably within 3 minutes, more preferably within 2.5 minutes, particularly within 2 minutes, and particularly within 1 minute, a local anesthetic. It is preferable that
- the surface anesthetic of the present invention further includes additives in conventionally known local anesthetics such as storage stabilizers (antioxidants such as butylhydroxytoluene and gallic acid esters, gelatin, agar, starch, thiourea, Stabilizers such as citric acid, L-methionine, glutamic acid, fructose, sucrose, lactose and thioglycerin), thickeners, fragrances, sweeteners, diluents, solvents and the like can be blended.
- Examples of the dosage form of the surface anesthetic of the present invention include liquid, jelly, ointment, seal (penless), etc. Examples of use include application, adhesion, spray (spraying), and sticking. Can be mentioned.
- As the anesthetic component it is convenient to use it by diluting the active ingredient to 0.1 to 50% by mass, preferably about 1 to 25% by mass with a solvent or other additives.
- As an application amount it can be set as the application amount similar to the conventional surface anesthetic.
- the surface anesthetic of the present invention is used in the same manner as conventionally known surface anesthetics. That is, it is applied to all mammals, and anesthesia is performed by attaching and penetrating especially on mucous membranes and skin. In general, it is used to reduce the puncture pain of an injection needle prior to infiltration anesthesia or transmission anesthesia by injection when performing surgery or the like.
- anesthesia is performed by attaching and penetrating especially on mucous membranes and skin.
- it is used to reduce the puncture pain of an injection needle prior to infiltration anesthesia or transmission anesthesia by injection when performing surgery or the like.
- reducing pain such as stomatitis, toothache, neuralgia, etc.
- for the purpose of reducing pain when inserting a needle when performing infusion and for the purpose of reducing pain when using an endoscope, colon fiber or nasal tube It is also possible to do.
- ethyl paraaminobenzoate (“Hurricane Gel (trademark)” manufactured by Daito Corporation: concentration 20% by mass), lidocaine (“Xylocaine Jelly (trademark)” manufactured by AstraZeneca Corporation: concentration 2% by mass), tetra Cain (“Corpalon (trademark)” manufactured by Showa Yakuhin Kako Co., Ltd .; 6 mass% solution) and adrenaline (“Bosmin liquid (trademark)” manufactured by Daiichi Sankyo Co., Ltd .: concentration 0.1 mass%) were used.
- the anesthetics were xylocaine jelly and hurricane gel in a ratio of 0: 200, 16: 184, 50: 150, 80: 120, 140: 60, 164: 36, 180: 20, 195: 5, 200: 0, respectively. It was prepared by blending. In the same manner as in Example 1, 200 mg of each prepared surface anesthetic was applied to the oral mucosa and then touched to measure the time until it became painless.
- FIG. 2 shows the relationship between the time until painlessness and the mass ratio between lidocaine and ethyl paraaminobenzoate.
- FIG. 2 shows that lidocaine alone is 5 minutes and ethyl paraaminobenzoate alone is 3 minutes and 30 seconds, whereas lidocaine: ethyl paraaminobenzoate has a mass ratio of 1:99 to 47:53 and 3 minutes after application. It turns out to be painless within. In particular, when the ratio (mass ratio) is in the range of 6:94 to 18:82, no pain is observed in about 2 minutes.
- Lidocaine (xylocaine jelly used in Example 1) 4 mg, adrenaline 0 mg (0 mass%), 0.002 mg (0.05 mass%), 0.01 mg (0.25 mass%), 0.04 mg (1 0.0 mass%) and 0.08 mg (2.0 mass%) were added, and the time until the surface anesthesia began to work was measured.
- the coating method and the measurement method for the results were the same as in Example 1.
- the results are shown in FIG.
- FIG. 3 shows 20 mg of ethyl paraaminobenzoate + 2 mg ( ⁇ O ⁇ ) of lidocaine, 20 mg of ethyl paraaminobenzoate + 2 mg of lidocaine + adrenaline, which are the first data in Example 1.
- the present invention is used as a surface anesthetic and an analgesic in the medical field, particularly oral surgery, urology, surgery, and the like.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
(2)リドカイン単独区(比較例1-2)では、キシロカインゼリー200mg(リドカイン4mg)を綿棒につけて、口腔粘膜に塗布した。
(3)パラアミノ安息香酸エチルとリドカイン併用区(実施例1-1)では、ハリケインゲルとキシロカインゼリーの等量混合物200mg(パラアミノ安息香酸エチル20mgとリドカイン2mg)を綿棒につけて、口腔粘膜に塗布した。
(4)パラアミノ安息香酸エチルとリドカインとアドレナリン三者併用区(実施例1-2)では、ハリケインゲルとキシロカインゼリーの等量混合物200mg(パラアミノ安息香酸エチル20mgとリドカイン2mg)とアドレナリン液10mg(アドレナリン0.01mg)を綿棒につけて、口腔粘膜に塗布した。
(1)テトラカイン単独区では、コーパロン200mg(テトラカイン12mg)を綿棒につけて、口腔粘膜に塗布した。
(2)リドカイン単独区では、キシロカインゼリー200mg(リドカイン4mg)を綿棒につけて、口腔粘膜に塗布した。
(3)テトラカインとリドカイン併用区では、コーパロンとキシロカインゼリーの配合比を、80:20、60:40、40:60、20:80と変えることにより、テトラカインとリドカインの質量比92:8、82:18、67:33、43:57の各種混合物を調製した。調製した各混合物200mgを綿棒につけて、口腔粘膜に塗布した。
(4)テトラカインとリドカインとアドレナリン三者併用区では、コーパロンとキシロカインゼリーの等量混合物200mg(テトラカイン6mgとリドカイン2mg)とアドレナリン液10mg(アドレナリン0.01mg)を綿棒につけて、口腔粘膜に塗布した。
Claims (8)
- リドカインとパラアミノ安息香酸エチルとを質量比1:99~47:53の割合で含むことを特徴とする表面麻酔剤。
- リドカインとパラアミノ安息香酸エチルとを質量比6:94~18:82の割合で含むことを特徴とする請求項1記載の表面麻酔剤。
- リドカインとパラアミノ安息香酸エチルに、さらにアドレナリンを含むことを特徴とする請求項1又は2記載の表面麻酔剤。
- リドカインとパラアミノ安息香酸エチルとの合計100質量部に対して、アドレナリンを0.1~0.001質量部を含むことを特徴とする請求項1~3のいずれか記載の表面麻酔剤。
- リドカインとパラアミノ安息香酸エチルとを質量比1:99~47:53の割合で含む組成物を表面麻酔剤製造のために使用する方法。
- 組成物が、リドカインとパラアミノ安息香酸エチルとを質量比6:94~18:82の割合で含むことを特徴とする請求項5記載の方法。
- 組成物が、リドカインとパラアミノ安息香酸エチルに、さらにアドレナリンを含むことを特徴とする請求項5又は6記載の方法。
- 組成物が、リドカインとパラアミノ安息香酸エチルとの合計100質量部に対して、アドレナリンを0.001~0.1質量部を含むことを特徴とする請求項5~7のいずれか記載の方法。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10793849.0A EP2450036B1 (en) | 2009-07-02 | 2010-06-30 | Surface anesthetic agent |
JP2011520788A JP5669145B2 (ja) | 2009-07-02 | 2010-06-30 | 表面麻酔剤 |
US13/379,107 US9107876B2 (en) | 2009-07-02 | 2010-06-30 | Surface anesthetic agent |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009-157425 | 2009-07-02 | ||
JP2009157425 | 2009-07-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011001676A1 true WO2011001676A1 (ja) | 2011-01-06 |
Family
ID=43410763
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2010/004312 WO2011001676A1 (ja) | 2009-07-02 | 2010-06-30 | 表面麻酔剤 |
Country Status (4)
Country | Link |
---|---|
US (1) | US9107876B2 (ja) |
EP (1) | EP2450036B1 (ja) |
JP (1) | JP5669145B2 (ja) |
WO (1) | WO2011001676A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014507473A (ja) * | 2011-03-07 | 2014-03-27 | スリーエム イノベイティブ プロパティズ カンパニー | マイクロニードルデバイス及び方法 |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0460884B2 (ja) | 1988-04-21 | 1992-09-29 | Biruherumu Toireru | |
JPH0977662A (ja) | 1995-09-11 | 1997-03-25 | Zeria Pharmaceut Co Ltd | 軟膏剤 |
JPH10306040A (ja) | 1997-05-07 | 1998-11-17 | Showa Yakuhin Kako Kk | 局所麻酔用組成物 |
JP2002275093A (ja) | 2001-01-10 | 2002-09-25 | Showa Yakuhin Kako Kk | 局所麻酔用組成物 |
JP2003512401A (ja) | 1999-10-25 | 2003-04-02 | エピセプト コーポレーション | 外科的に閉じた創傷部からの疼痛の局所的抑制または改善 |
JP2003532678A (ja) | 2000-05-12 | 2003-11-05 | ノバラー ファーマシューティカルズ, インコーポレイテッド | 局所麻酔の方法およびキット |
JP2006527734A (ja) | 2003-06-19 | 2006-12-07 | フィタ,フェルナンド ボウファルド | 局所投与のための麻酔用組成物 |
WO2007055279A1 (ja) * | 2005-11-14 | 2007-05-18 | Teikoku Seiyaku Co., Ltd. | イオントフォレーシス用製剤 |
JP2007262030A (ja) | 2006-03-29 | 2007-10-11 | Kobayashi Pharmaceut Co Ltd | 皮膚外用剤 |
JP2008029681A (ja) * | 2006-07-31 | 2008-02-14 | Nipro Corp | 薬剤充填容器 |
JP2009506076A (ja) * | 2005-08-26 | 2009-02-12 | ザ・ボード・オブ・トラスティーズ・オブ・ザ・レランド・スタンフォード・ジュニア・ユニバーシティ | 三叉神経疼痛のための薬物送達のための治療手順 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2230448A1 (en) | 1995-08-28 | 1997-03-06 | Showa Yakuhin Kako Co., Ltd. | Composition for local anesthesia |
US5885597A (en) * | 1997-10-01 | 1999-03-23 | Medical Research Industries,Inc. | Topical composition for the relief of pain |
US20060127429A1 (en) * | 2004-12-13 | 2006-06-15 | Mccartt Mary D | Topical numbing composition for laser therapy |
US20090053290A1 (en) | 2006-03-08 | 2009-02-26 | Sand Bruce J | Transdermal drug delivery compositions and topical compositions for application on the skin |
EP2086320A4 (en) * | 2006-09-21 | 2011-04-20 | Coastal Solutions Inc | COMPOSITIONS AND METHODS FOR TREATING MEDUSES |
-
2010
- 2010-06-30 JP JP2011520788A patent/JP5669145B2/ja active Active
- 2010-06-30 WO PCT/JP2010/004312 patent/WO2011001676A1/ja active Application Filing
- 2010-06-30 EP EP10793849.0A patent/EP2450036B1/en active Active
- 2010-06-30 US US13/379,107 patent/US9107876B2/en active Active
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0460884B2 (ja) | 1988-04-21 | 1992-09-29 | Biruherumu Toireru | |
JPH0977662A (ja) | 1995-09-11 | 1997-03-25 | Zeria Pharmaceut Co Ltd | 軟膏剤 |
JPH10306040A (ja) | 1997-05-07 | 1998-11-17 | Showa Yakuhin Kako Kk | 局所麻酔用組成物 |
JP2003512401A (ja) | 1999-10-25 | 2003-04-02 | エピセプト コーポレーション | 外科的に閉じた創傷部からの疼痛の局所的抑制または改善 |
JP2003532678A (ja) | 2000-05-12 | 2003-11-05 | ノバラー ファーマシューティカルズ, インコーポレイテッド | 局所麻酔の方法およびキット |
JP2002275093A (ja) | 2001-01-10 | 2002-09-25 | Showa Yakuhin Kako Kk | 局所麻酔用組成物 |
JP2006527734A (ja) | 2003-06-19 | 2006-12-07 | フィタ,フェルナンド ボウファルド | 局所投与のための麻酔用組成物 |
JP2009506076A (ja) * | 2005-08-26 | 2009-02-12 | ザ・ボード・オブ・トラスティーズ・オブ・ザ・レランド・スタンフォード・ジュニア・ユニバーシティ | 三叉神経疼痛のための薬物送達のための治療手順 |
WO2007055279A1 (ja) * | 2005-11-14 | 2007-05-18 | Teikoku Seiyaku Co., Ltd. | イオントフォレーシス用製剤 |
JP2007262030A (ja) | 2006-03-29 | 2007-10-11 | Kobayashi Pharmaceut Co Ltd | 皮膚外用剤 |
JP2008029681A (ja) * | 2006-07-31 | 2008-02-14 | Nipro Corp | 薬剤充填容器 |
Non-Patent Citations (3)
Title |
---|
J. GEN. PHYSIOL., vol. 71, no. 2, 1978, pages 223 - 225, XP008148645 * |
PFLUGERS ARCH., vol. 387, no. 1, 1980, pages 47 - 54, XP008148642 * |
See also references of EP2450036A4 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014507473A (ja) * | 2011-03-07 | 2014-03-27 | スリーエム イノベイティブ プロパティズ カンパニー | マイクロニードルデバイス及び方法 |
JP2017105784A (ja) * | 2011-03-07 | 2017-06-15 | スリーエム イノベイティブ プロパティズ カンパニー | マイクロニードルデバイス及び方法 |
Also Published As
Publication number | Publication date |
---|---|
EP2450036A4 (en) | 2012-12-26 |
EP2450036B1 (en) | 2016-06-15 |
JP5669145B2 (ja) | 2015-02-12 |
US20120101158A1 (en) | 2012-04-26 |
JPWO2011001676A1 (ja) | 2012-12-10 |
EP2450036A1 (en) | 2012-05-09 |
US9107876B2 (en) | 2015-08-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5148271B2 (ja) | 疼痛処置のためのカプサイシノイド、局所麻酔薬および/または鎮痒薬を含有する処方物 | |
Ogle et al. | Local anesthesia: agents, techniques, and complications | |
Silvestre et al. | Clinical study of hemodynamic changes during extraction in controlled hypertensive patients | |
US20040131665A1 (en) | Topical anesthetic formulation | |
US20050014823A1 (en) | Topical anesthetic composition and method of administration | |
US10391074B2 (en) | Topical preparation for pain relief | |
Mohite et al. | Comparative evaluation of a novel herbal anesthetic gel and 2% lignocaine gel as an intraoral topical anesthetic agent in children: Bilateral split-mouth, single-blind, crossover: in vivo: study | |
JP5669145B2 (ja) | 表面麻酔剤 | |
RU2011139015A (ru) | Вызываемая медикаментозными средствами липоатрофия для косметических целей | |
ES2658287T3 (es) | Composición para el tratamiento de verrugas | |
Ramacciato et al. | Recent advances in local anaesthesia | |
JP2012193159A (ja) | 鼻用スプレー | |
AlWeshah et al. | Effectiveness of 5% EMLA cream versus 20% Benzocaine gel as topical anesthetics in Dentistry | |
Grover et al. | An approach towards painless administration of local anaesthetic agents in pediatric dentistry: In vivo study | |
JP7169633B2 (ja) | 表面麻酔剤 | |
JP7450916B2 (ja) | 表面麻酔剤 | |
Ito et al. | Anesthetic duration of lidocaine with 10% dextran is comparable to lidocaine with 1: 160 000 epinephrine after intraosseous injection in the rabbit | |
US11642328B2 (en) | Creatine, its derivatives, compositions and methods of use thereof | |
Thaminee | Articaine in dentistry | |
Satılmış et al. | A new and enhanced version of local anesthetics in dentistry | |
Kramer et al. | Overview of Local Anesthesia | |
Gehlot | Attenuation of pressor response to laryngoscopy and intubation: dexmedetomidine Vs. fentanyl premedication | |
RU2323721C2 (ru) | Местноанестезирующее и антисептическое средство | |
WO2009157377A1 (ja) | 口腔内麻酔剤 | |
Soliman et al. | Effective dose of perineural dexmedetomidine in great auricular nerve block: a randomized control study |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10793849 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2011520788 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010793849 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13379107 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |